Topic Compilations

Topic Compilations

Each of our Topic Compilations includes a collection of features and news articles published in ASH Clinical News related to a specific hematologic disorder.

First Biosimilar for Rituximab Gains Approval

The FDA approved rituximab-abbs, the first biosimilar of rituximab, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL). This marks the...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...

FDA Approves Frontline Venetoclax for AML

The BCL2 inhibitor venetoclax, in combination with azacitidine or decitabine or low-dose cytarabine, was approved by the FDA for the treatment of patients with...

Glasdegib Receives Approval for Older Patients With AML

The FDA approved glasdegib, in combination with low-dose cytarabine, for patients with newly diagnosed AML who are aged 75 years or older or who...

Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia

Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...
WIB_icon

Can a Selinexor Combination STOMP Out Relapsed/Refractory Multiple Myeloma?

The combination of selinexor plus low-dose bortezomib and dexamethasone produced high response rates in patients with relapsed or refractory multiple myeloma (MM), with a...

Apixaban Superior to LMWH in Reducing Recurrence of Cancer-Associated VTE

Results from a trial presented at the 2018 ASH Annual Meeting add more support for the use of direct oral anticoagulants in patients with...

First-in-Human Trial Shows AMG 330 Is Tolerable in Relapsed/Refractory AML

AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, was generally tolerable and demonstrated anti-leukemic activity in patients with relapsed/refractory acute myeloid leukemia...

For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...

FDA Expands Dasatinib’s Approval to Pediatric Ph-Positive ALL

The U.S. Food and Drug Administration (FDA) expanded the approval of dasatinib to include the treatment of pediatric patients (≥1 year of age) with...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.